Article
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2021
Smith Catherine C, Viny Aaron D, Massi Evan, Kandoth Cyriac, Socci Nicholas D, Rapaport Franck, Najm Matthieu, Medina-Martinez Juan S, Papaemmanuil Elli, Tarver Theodore C, Hsu Henry H, Le Mai H, West Brian, Bollag Gideon, Taylor Barry S, Levine Ross L, Shah Neil P
Abstract excerpt
PURPOSE: Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are still emerging, and optimal clinical combinations remain unclear. The purpose of this study is to identify co-occurring mutations that influence clinical response to the novel FLT3 inhibitor pexidartinib (PLX3397). EXPERIMENTAL DESIGN: We performed targeted sequencing of pretreatment blasts from 29 patients with FLT3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.